Georgina V Long

Summary

Publications

  1. doi Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
    Georgina V Long
    Georgina V Long, Melanoma Institute Australia The University of Sydney Richard F Kefford, Melanoma Institute Australia The University of Sydney Macquarie University, Sydney Westmead Hospital, Westmead Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia Jeffrey S Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL Jeffrey R Infante and Howard A Burris III, Sarah Cannon Research Institute Tennessee Oncology Kevin B Kim, California Pacific Medical Center Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA Rene Gonzalez, Karl Lewis, University of Colorado Gerald S Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO Jeffrey A Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN Lynn Schuchter, University of Pennsylvania Abramson Cancer Center Nageatte Ibrahim, Elizabeth Cunningham, Merck Peng Sun, Amy S Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia
    J Clin Oncol 34:871-8. 2016
  2. doi Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
    Georgina V Long
    Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia Mater Hospital, Sydney, NSW, Australia Electronic address
    Lancet 386:444-51. 2015
  3. pmc Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling
    Andy J Chien
    Division of Dermatology, University of Washington Department of Medicine, Seattle, Washington, United States of America The Group Health Research Institute, Seattle, Washington, United States of America
    PLoS ONE 9:e94748. 2014
  4. doi Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression
    Georgina V Long
    Melanoma Institute Australia, Sydney, NSW, Australia
    Pigment Cell Melanoma Res 26:499-508. 2013
  5. doi Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma
    Georgina V Long
    Melanoma Institute Australia and Westmead Hospital, 40 Rocklands Rd, North Sydney, NSW 2060, Australia
    Am J Surg Pathol 37:61-5. 2013
  6. doi Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
    Georgina V Long
    Melanoma Institute Australia, Westmead Institute for Cancer Research, and Westmead Hospital, The University of Sydney, Sydney, NSW, Australia
    Lancet Oncol 13:1087-95. 2012
  7. doi Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
    Georgina V Long
    Melanoma Institute Australia, 40 Rocklands Rd, North Sydney, New South Wales, 2060, Australia
    J Clin Oncol 29:1239-46. 2011
  8. doi Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma
    James S Wilmott
    Melanoma Institute Australia, Sydney, NSW, Australia
    Clin Cancer Res 18:1386-94. 2012
  9. pmc Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors
    Hubing Shi
    Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90095 1750, USA
    Cancer Discov 2:414-24. 2012
  10. doi Intrapatient homogeneity of BRAFV600E expression in melanoma
    Alexander M Menzies
    Melanoma Institute Australia Discipline of Medicine Pathology Surgery, The University of Sydney Departments of Melanoma and Surgical Oncology Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital Department of Medicine, Westmead Hospital Westmead Institute for Cancer Research, Westmead Hospital The Kinghorn Cancer Centre, Garvan Institute of Medical Research St Vincent s Clinical School, University of New South Wales, Sydney, Australia
    Am J Surg Pathol 38:377-82. 2014

Detail Information

Publications61

  1. doi Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
    Georgina V Long
    Georgina V Long, Melanoma Institute Australia The University of Sydney Richard F Kefford, Melanoma Institute Australia The University of Sydney Macquarie University, Sydney Westmead Hospital, Westmead Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia Jeffrey S Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL Jeffrey R Infante and Howard A Burris III, Sarah Cannon Research Institute Tennessee Oncology Kevin B Kim, California Pacific Medical Center Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA Rene Gonzalez, Karl Lewis, University of Colorado Gerald S Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO Jeffrey A Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN Lynn Schuchter, University of Pennsylvania Abramson Cancer Center Nageatte Ibrahim, Elizabeth Cunningham, Merck Peng Sun, Amy S Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia
    J Clin Oncol 34:871-8. 2016
    ....
  2. doi Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
    Georgina V Long
    Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia Mater Hospital, Sydney, NSW, Australia Electronic address
    Lancet 386:444-51. 2015
    ..The study was continued to assess the secondary endpoint of overall survival, which we report in this Article...
  3. pmc Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling
    Andy J Chien
    Division of Dermatology, University of Washington Department of Medicine, Seattle, Washington, United States of America The Group Health Research Institute, Seattle, Washington, United States of America
    PLoS ONE 9:e94748. 2014
    ..Understanding these pathway interactions will be necessary to facilitate efforts to individualize therapies for melanoma patients. ..
  4. doi Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression
    Georgina V Long
    Melanoma Institute Australia, Sydney, NSW, Australia
    Pigment Cell Melanoma Res 26:499-508. 2013
    ..The addition of therapies targeting the cell cycle machinery may improve the response and duration of BRAFi, and investigation of the mechanisms of apoptosis may provide additional therapeutic targets. ..
  5. doi Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma
    Georgina V Long
    Melanoma Institute Australia and Westmead Hospital, 40 Rocklands Rd, North Sydney, NSW 2060, Australia
    Am J Surg Pathol 37:61-5. 2013
    ..Clinical use of the V600E BRAF antibody should be a valuable supplement to conventional mutation testing and allow V600E mutant metastatic melanoma patients to be triaged rapidly into appropriate treatment pathways...
  6. doi Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
    Georgina V Long
    Melanoma Institute Australia, Westmead Institute for Cancer Research, and Westmead Hospital, The University of Sydney, Sydney, NSW, Australia
    Lancet Oncol 13:1087-95. 2012
    ..We assessed dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain...
  7. doi Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
    Georgina V Long
    Melanoma Institute Australia, 40 Rocklands Rd, North Sydney, New South Wales, 2060, Australia
    J Clin Oncol 29:1239-46. 2011
    ..To assess the frequency and type of oncogenic BRAF mutations in metastatic melanoma and correlate BRAF status with clinicopathologic features and outcome...
  8. doi Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma
    James S Wilmott
    Melanoma Institute Australia, Sydney, NSW, Australia
    Clin Cancer Res 18:1386-94. 2012
    ..To evaluate the effects of treatment with the potent mutant BRAF inhibitors GSK2118436 or vemurafenib (PLX4720) on immune responses to metastatic melanoma in tissues taken before and after treatment...
  9. pmc Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors
    Hubing Shi
    Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90095 1750, USA
    Cancer Discov 2:414-24. 2012
    ..Thus, activating MEK1 exon 3 mutations identified herein and concurrent with V600E/KBRAF do not cause BRAFi resistance in melanoma...
  10. doi Intrapatient homogeneity of BRAFV600E expression in melanoma
    Alexander M Menzies
    Melanoma Institute Australia Discipline of Medicine Pathology Surgery, The University of Sydney Departments of Melanoma and Surgical Oncology Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital Department of Medicine, Westmead Hospital Westmead Institute for Cancer Research, Westmead Hospital The Kinghorn Cancer Centre, Garvan Institute of Medical Research St Vincent s Clinical School, University of New South Wales, Sydney, Australia
    Am J Surg Pathol 38:377-82. 2014
    ....
  11. doi Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment
    James S Wilmott
    Melanoma Institute Australia, Sydney, New South Wales 2060, Australia
    J Immunol 192:2505-13. 2014
    ..Further studies are needed to determine if CXCL8 is predictive of response and to confirm the functions of these chemokine and cytokine in BRAF-mutant melanoma under BRAF inhibition. ..
  12. doi BRAF inhibitor activity in V600R metastatic melanoma
    Oliver Klein
    Melanoma Institute Australia and Westmead Hospital, University of Sydney, 40 Rocklands Road, North Sydney, New South Wales, Australia
    Eur J Cancer 49:1073-9. 2013
    ..Our experience suggests that patients with V600R BRAF mutations can be treated successfully with oral BRAF inhibitors, and molecular diagnostic assays should include detection of this type of mutation...
  13. doi Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma
    Alexander M Menzies
    Melanoma Institute Australia, Disciplines of Medicine, Surgery, Pathology, and Westmead Institute for Cancer Research, Westmead Millennium Institute, The University of Sydney, Sydney, New South Wales, Australia
    Clin Cancer Res 18:3242-9. 2012
    ..This study sought to determine the BRAF mutation status by age-decade and whether BRAF-mutant genotypes correlated with clinicopathologic features and outcome in patients with metastatic melanoma...
  14. doi Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients
    Matteo S Carlino
    Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead, New South Wales, Australia Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, New South Wales, Australia Melanoma Institute Australia, Sydney, New South Wales, Australia
    Clin Cancer Res 21:98-105. 2015
    ..We sought to determine whether recurrent, preexisting MEK1(P124) mutations affected clinical outcome in BRAF inhibitor-treated patients with melanoma...
  15. doi Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib
    Mary W F Azer
    Westmead Hospital, Westmead, Australia Melanoma Institute Australia, Sydney, Australia
    Cancer 120:530-6. 2014
    ..This study sought to examine the intracranial (IC) and extracranial (EC) patterns of response and progression in patients with active melanoma brain metastases treated with dabrafenib...
  16. doi Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine
    James S Wilmott
    Melanoma Institute Australia, Australia
    Mol Cancer Ther 11:2704-8. 2012
    ....
  17. pmc Dabrafenib and its potential for the treatment of metastatic melanoma
    Alexander M Menzies
    Melanoma Institute Australia, Sydney, New South Wales, Australia
    Drug Des Devel Ther 6:391-405. 2012
    ..It is expected that new combinations of targeted drugs, such as the combination of dabrafenib and trametinib (GSK1120212, a MEK inhibitor), will provide higher response rates and more durable clinical benefit than dabrafenib monotherapy...
  18. doi Incidence of new primary melanomas after diagnosis of stage III and IV melanoma
    Lisa Zimmer
    Lisa Zimmer and Dirk Schadendorf, University Hospital, University Duisburg Essen, Essen, Germany Lauren E Haydu, Alexander M Menzies, Richard A Scolyer, Richard F Kefford, John F Thompson, and Georgina V Long, Melanoma Institute Australia Alexander M Menzies, Richard A Scolyer, Richard F Kefford, and Georgina V Long, Sydney Medical School, The University of Sydney Richard A Scolyer and John F Thompson, Royal Prince Alfred Hospital Lauren E Haydu and John F Thompson, The University of Sydney John F Thompson, Mater Hospital, Sydney Richard F Kefford and Georgina V Long, Westmead Institute for Cancer Research, Westmead Hospital, Westmead, New South Wales, Australia
    J Clin Oncol 32:816-23. 2014
    ..We sought to determine the background incidence of spontaneous NPMs after a diagnosis of American Joint Committee on Cancer/International Union Against Cancer stage III or IV melanoma in patients not treated with a BRAF inhibitor...
  19. doi PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients
    Hojabr Kakavand
    Melanoma Institute Australia, North Sydney, New South Wales, Australia Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
    Clin Cancer Res 21:3140-8. 2015
    ..To evaluate the expression of tumor PD-L1 and changes in tumor-infiltrating lymphocyte (TIL) populations in patients with metastatic melanoma treated with targeted MAPK inhibitors...
  20. doi Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma
    Matteo S Carlino
    Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, New South Wales, Australia
    Mol Oncol 8:544-54. 2014
    ..Our data indicate that a broader targeting strategy concurrently inhibiting ERK, rather than MEK, and PI3K/mTOR may circumvent BRAF inhibitor resistance, and should be considered during the clinical development of ERK inhibitors. ..
  21. doi Paradoxical oncogenesis: are all BRAF inhibitors equal?
    Alexander M Menzies
    Melanoma Institute Australia, Sydney, NSW, Australia
    Pigment Cell Melanoma Res 26:611-5. 2013
    ....
  22. doi (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma
    Matteo S Carlino
    Westmead Millennium Institute, The University of Sydney, Sydney, Australia
    Eur J Cancer 49:395-402. 2013
    ..We aim to determine the prevalence, and clinicopathologic correlates of intra-patient heterogeneity of FDG-PET response in metastatic melanoma treated with dabrafenib, and to determine whether heterogeneity predicts clinical outcome...
  23. doi The molecular profile of metastatic melanoma in Australia
    Megan Lyle
    Melanoma Institute Australia, Sydney, NSW, Australia The University of Sydney, Sydney, NSW, Australia Liz Plummer Cancer Centre, Cairns, QLD, Australia
    Pathology 48:188-93. 2016
    ..NRAS mutations are more prevalent than initially described; however, other mutations reported in melanoma, including KIT, are rare in an unselected population of patients. ..
  24. pmc Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor
    Douglas B Johnson
    Douglas B Johnson and Jeffrey A Sosman, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center Jeffrey R Infante and Howard A Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN Keith T Flaherty and Donald P Lawrence, Massachusetts General Hospital Cancer Center, Boston MA Jeffrey S Weber and Geoffrey T Gibney, Moffitt Cancer Center, Tampa, FL Kevin B Kim and Gerald S Falchook, University of Texas MD Anderson Cancer Center, Houston, TX Richard F Kefford and Georgina V Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales Jonathan Cebon, Joint Ludwig Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia Omid Hamid, Angeles Clinic and Research Institute, Los Angeles Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA Lynn Schuchter, University of Pennsylvania Abramson Cancer Center Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA William H Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD Robert R McWilliams, Mayo Clinic
    J Clin Oncol 32:3697-704. 2014
    ..This study assessed the safety and efficacy of dabrafenib and trametinib in patients who had received prior BRAF inhibitor treatment...
  25. pmc Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
    Hubing Shi
    1Division of Dermatology, Department of Medicine, 2Division of Surgical Oncology, Department of Surgery, 3Division of Hematology and Oncology, Department of Medicine 4Jonsson Comprehensive Cancer Center 5Department of Molecular and Medical Pharmacology 6David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California Departments of 7Medicine, 8Cancer Biology, and 9Surgery, 10Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 11Melanoma Institute of Australia, Westmead Millennium Institute, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia and 12Ludwig Institute for Cancer Research, Brussels Branch, Belgium
    Cancer Discov 4:80-93. 2014
    ..Thus, melanoma genomic heterogeneity contributes significantly to BRAF inhibitor treatment failure, implying upfront, cotargeting of two core pathways as an essential strategy for durable responses. ..
  26. doi Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma
    Matteo S Carlino
    Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW 2145, Australia
    Mol Cancer Ther 12:1332-42. 2013
    ..These data provide a rationale for the continuation of BRAF and MEK inhibitors after disease progression and support the development of clinical trials to examine this strategy...
  27. doi Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases
    Hojabr Kakavand
    Melanoma Institute Australia, North Sydney, NSW, Australia
    Mod Pathol 28:1535-44. 2015
    ....
  28. doi Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma
    Paolo A Ascierto
    Paolo A Ascierto, Ester Simeone, Instituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy David Minor, California Pacific Center for Melanoma Research and Treatment, San Francisco Antoni Ribas, Jonsson Comprehensive Cancer Center, University of California, Los Angeles Omid Hamid, Experimental Therapeutics Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles, CA Anne O Hagan, Niki Arya, Mary Guckert, Anne Marie Martin, Jolly Mazumdar, Vicki L Goodman, GlaxoSmithKline Oncology, Collegeville Ravi Amaravadi, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA Kevin B Kim, The University of Texas MD Anderson Cancer Center, Houston, TX Celeste Lebbe, Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Paris, Universite Paris Diderot, Paris Jean Jacques Grob, Aix Marseille University, Assistance Publique Hopitaux de Marseille, Hopital Timone, Marseille, Halifax
    J Clin Oncol 31:3205-11. 2013
    ..Dabrafenib (GSK2118436) is a potent inhibitor of mutated BRAF kinase. Our multicenter, single-arm, phase II study assessed the safety and clinical activity of dabrafenib in BRAF(V600E/K) mutation-positive metastatic melanoma (mut(+) MM)...
  29. doi BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact
    Helen Rizos
    Authors Affiliations Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute Departments of Medical Oncology and Surgical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead Melanoma Institute Australia Disciplines of Pathology, Medicine, and Surgery, Sydney Medical School, The University of Sydney, Sydney Departments of Melanoma and Surgical Oncology and Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
    Clin Cancer Res 20:1965-77. 2014
    ..Multiple BRAF inhibitor resistance mechanisms have been described, however, their relative frequency, clinical correlates, and effect on subsequent therapy have not been assessed in patients with metastatic melanoma...
  30. doi The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition
    Matthew M K Chan
    Melanoma Institute Australia, Sydney, New South Wales, Australia Department of Medical Oncology, Crown Princess Mary Cancer Center, Westmead Hospital, Sydney, New South Wales, Australia University of Sydney, Sydney, New South Wales, Australia
    Cancer 120:3142-53. 2014
    ..In this study, the authors examined the nature and management of disease progression (PD) on BRAFi treatment, including characteristics and outcomes of patients who received continued BRAFi treatment beyond disease progression (TBP)...
  31. doi Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
    Georgina V Long
    1 Melanoma Institute Australia, Sydney, New South Wales 2060, Australia 2 Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia 3 Mater Hospital, North Sydney, New South Wales 2060, Australia
    Nat Commun 5:5694. 2014
    ..Nevertheless, most melanomas carried additional oncogenic mutations at baseline (for example, RAC1 and AKT3) that activate the MAPK and PI3K pathways and are thus predicted to diminish response to MAPK inhibitors. ..
  32. doi Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma
    Rajmohan Murali
    Melanoma Institute Australia, Sydney, New South Wales, Australia
    Cancer 118:4519-29. 2012
    ..The authors sought to address the latter question in the current study...
  33. doi Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors
    Alexander M Menzies
    Melanoma Institute Australia, Sydney, Australia
    Cancer 121:3826-35. 2015
    ..Whether baseline clinicopathologic factors can predict the clinical course with treatment is largely unknown...
  34. doi Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma
    James S Wilmott
    1 Melanoma Institute Australia, Sydney, New South Wales, Australia 2 Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
    Mod Pathol 28:884-94. 2015
    ..These results suggest not only that HDAC8 may be a prognostic biomarker in melanoma, but also provide important data regarding the regulation of HDACs in melanoma and a rational basis for targeting them therapeutically. ..
  35. pmc A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition
    Hubing Shi
    1The Division of Dermatology, Department of Medicine, 2Division of Surgical Oncology, Department of Surgery, 3Division of Hematology and Oncology, Department of Medicine, 4Jonsson Comprehensive Cancer Center, 5Department of Molecular and Medical Pharmacology, 6David Geffen School of Medicine, University of California, Los Angeles, California 7Melanoma Institute of Australia, 8Royal Prince Alfred Hospital, 9Westmead Millennium Institute, and 10Westmead Hospital, University of Sydney, New South Wales, Australia
    Cancer Discov 4:69-79. 2014
    ..In addition, mitogen-activated protein kinase pathway inhibition enhanced clonogenic growth dependency on PI3K or AKT. Thus, adaptive or genetic upregulation of AKT critically participates in melanoma survival during BRAFi therapy. ..
  36. doi Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas
    Hojabr Kakavand
    1The University of Sydney, Sydney 2Melanoma Institute Australia, North Sydney 3Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia 4Canterbury Health Laboratories, Christchurch, New Zealand 5Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst 6Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
    Pathology 46:193-8. 2014
    ..The findings have important implications for adjuvant clinical trials of targeted therapies...
  37. doi PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
    Jason Madore
    Melanoma Institute Australia, Sydney, NSW, Australia Sydney Medical School, The University of Sydney, Sydney, NSW, Australia
    Pigment Cell Melanoma Res 28:245-53. 2015
    ..In locoregional lymph node metastasis, PD-L1+/TIL+ patients had the best outcome, and PD-L1+/TIL- patients had poor outcome...
  38. doi Cutaneous toxicities of RAF inhibitors
    Rachael Anforth
    Department of Dermatology, Westmead Hospital, Sydney, NSW, Australia
    Lancet Oncol 14:e11-8. 2013
    ..These disorders often affect patients' quality of life; therefore, dermatological assessment and timely management is essential to ensure that patients continue to use RAF inhibitors...
  39. doi Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma
    Rajmohan Murali
    Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
    Ann Surg Oncol 19:1782-9. 2012
    ..We sought to identify clinical and pathologic factors associated with distant metastasis and survival in a large number of patients with thin melanoma treated at a single institution...
  40. pmc Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
    Hubing Shi
    Division of Dermatology, Department of Medicine, University of California, Los Angeles, 52 121 CHS, 10833 Le Conte Avenue, California 90095 1750, USA
    Nat Commun 3:724. 2012
    ..Thus, alternative clinical strategies may potentially overcome distinct modes of extracellular signal-regulated kinase reactivation underlying acquired B-RAF inhibitor resistance in melanoma...
  41. doi Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy
    Rachael Anforth
    Department of Dermatology, Westmead Hospital, Westmead, Australia Sydney Medical School, University of Sydney, Sydney, Australia
    J Am Acad Dermatol 72:809-15.e1. 2015
    ..BRAF inhibitors (BRAFi) cause paradoxical activation of the MAPK pathway in keratinocytes resulting in cutaneous squamous cell carcinoma (cuSCC)...
  42. doi Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making
    Ricardo De Paoli-Iseppi
    Melanoma Institute Australia, North Sydney, NSW, Australia
    Pathology 48:261-6. 2016
    ....
  43. pmc Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
    Douglas B Johnson
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA Electronic address
    Eur J Cancer 51:2792-9. 2015
    ..In this study, we evaluated the spectrum, onset, pattern of progression, and subsequent clinical outcomes associated with specific mechanisms of resistance...
  44. doi Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
    Douglas B Johnson
    Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
    JAMA Oncol 2:234-40. 2016
    ..Autoimmune diseases are common, and the safety and efficacy of ipilimumab therapy in patients with preexisting autoimmune disorders is not known...
  45. doi Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma
    Clara I Lee
    aWestmead Hospital bWestmead Institute for Cancer Research, Westmead cMelanoma Institute Australia dSydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
    Melanoma Res 24:468-74. 2014
    ..Pyrexia does not correlate with clinical outcome. Neither DR nor antipyretics are effective secondary prophylaxis, whereas corticosteroids are effective, prevent DR and enable re-escalation of CombiDT dosing...
  46. doi Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
    Alexander M Menzies
    Melanoma Institute Australia, Sydney, Australia The University of Sydney, Sydney, Australia
    Eur J Cancer 49:3229-41. 2013
    ....
  47. pmc Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma
    Alexander M Menzies
    Melanoma Institute Australia, Sydney, Australia The University of Sydney, Sydney, Australia
    PLoS ONE 9:e85004. 2014
    ..We sought to examine the patterns of response and progression in patients treated with targeted therapy...
  48. doi Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists
    Hojabr Kakavand
    Melanoma Institute Australia, North Sydney, Australia The University of Sydney, Sydney, Australia
    Pathology 48:194-202. 2016
    ..Ultimately it may be the responsibility of the pathologist to identify which therapy or combination of therapies is most likely to benefit individual patients. ..
  49. doi Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma
    Matteo S Carlino
    Departments of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia Centre for Cancer Research, Westmead Millennium Institute, Westmead, New South Wales, Australia Melanoma Institute Australia, Sydney, New South Wales, Australia The Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia Electronic address
    Crit Rev Oncol Hematol 96:385-98. 2015
    ....
  50. pmc TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells
    Selina K Sutton
    Children s Cancer Institute, Lowy Cancer Research Centre, UNSW Australia, Sydney, Australia
    Oncotarget 5:10127-39. 2014
    ..Our data, for the first time, demonstrates TRIM16 is a marker of cell migration and metastasis, and a novel treatment target in melanoma. ..
  51. doi Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib
    Rachael Anforth
    Department of Dermatology, Westmead Hospital, Sydney, New South Wales, Australia Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
    Australas J Dermatol 55:250-4. 2014
    ..One of the most frequent side-effects associated with its use as a single agent is the development of acneiform eruptions. These eruptions seem to be reduced when dosed in combination with dabrafenib...
  52. pmc Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
    Ravi K Amaravadi
    Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
    Clin Cancer Res 21:5215-21. 2015
    ..BRAF inhibitors (BRAFi) extend survival in BRAF-mutant melanoma but can promote the growth of Ras-mutant neoplasms. This study determined if gastrointestinal polyps found in BRAFi-treated patients harbored Ras mutations...
  53. doi Diagnosis and treatment of KIT-mutant metastatic melanoma
    Megan Lyle
    Melanoma Institute Australia, Sydney, New South Wales, Australia
    J Clin Oncol 31:3176-81. 2013
    ..However, Sanger sequencing of KIT exons 9, 11, 13, and 17, performed as screening for a clinical trial enrolling patients with metastatic acral and mucosal melanomas, showed an exon 13 K642E mutation. ..
  54. doi Treatment of melanoma brain metastases: a new paradigm
    Matteo S Carlino
    Westmead Institute for Cancer Research, Westmead Millennium Institute, Sydney, Australia
    Cancer J 18:208-12. 2012
    ..We present a new treatment algorithm for melanoma patients with brain metastases, which integrates the evolving evidence for the use of BRAF inhibitors...
  55. doi Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care
    Richard A Scolyer
    Melanoma Institute Australia, Sydney, NSW, Australia
    Mol Oncol 5:124-36. 2011
    ..Whilst there remains much to be discovered in this rapidly evolving field, there is already great optimism that more rational and effective therapies for melanoma patients will soon be widely available...
  56. pmc Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis
    Tiffany J Parmenter
    1Molecular Oncology Laboratory, Oncogenic Signaling and Growth Control Program, 2Translational Research Laboratory, Cancer Therapeutics Program, 3Bioinformatics Core Facility, 4The Cancer Signalling Laboratory, Oncogenic Signaling and Growth Control Program, 5Gene Regulation Laboratory, Cancer Therapeutics Program, 6Molecular Imaging and Targeted Therapeutics Laboratory, Cancer Therapeutics Program, 7Department of Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne 8Sir Peter MacCallum Department of Oncology, Departments of 9Biochemistry and Molecular Biology, and 10Pathology, University of Melbourne, Parkville 11Metabolic Remodelling Laboratory, Metabolic Research Unit, School of Medicine, Deakin University, Waurn Ponds 12Department of Medicine, St Vincent s Hospital, University of Melbourne, Fitzroy, Victoria 13Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead 14Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital 15Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia 16Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Kyorin University School of Health Sciences
    Cancer Discov 4:423-33. 2014
    ..Thus, we provide a proof-of-principle for treatment of melanoma with combinations of BRAFis and glycolysis inhibitors...
  57. doi Systemic therapies for melanoma brain metastases: which drug for whom and when?
    Sangeetha Ramanujam
    Melanoma Institute Australia, Sydney, Australia
    Chin Clin Oncol 4:25. 2015
    ..This review will examine the evidence for systemic therapies in patients with active melanoma brain metastasis (untreated or treated and progressed) and highlight active and evolving clinical trials in this challenging field. ..
  58. doi Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma
    Samantha E Bowyer
    aDepartment of Medical Oncology, Cancer Centre, Sir Charles Gairdner Hospital bSchool of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia cPeter MacCallum Cancer Centre, East Melbourne dSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria eMelanoma Institute Australia, North Sydney fUniversity of Sydney, Sydney, New South Wales, Australia
    Melanoma Res 24:504-8. 2014
    ..Trametinib toxicity was manageable. Trametinib has antitumour activity in patients with BRAF K601E and L597Q mutation-positive metastatic melanoma...
  59. doi Systemic treatment for BRAF-mutant melanoma: where do we go next?
    Alexander M Menzies
    Melanoma Institute Australia, Sydney, NSW, Australia University of Sydney, Sydney, NSW, Australia
    Lancet Oncol 15:e371-81. 2014
    ....
  60. doi Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma
    Alexander M Menzies
    Authors Affiliation Melanoma Institute Australia and the University of Sydney, Sydney, Australia
    Clin Cancer Res 20:2035-43. 2014
    ..Here, we review the clinical development of both drugs as monotherapies and in combination, and discuss their role in the management of BRAF-mutant melanoma...
  61. doi The role of systemic therapies in the management of melanoma brain metastases
    Megan Lyle
    aMelanoma Institute Australia bThe University of Sydney, Sydney, Australia
    Curr Opin Oncol 26:222-9. 2014
    ..This review will focus on new systemic therapies for metastatic melanoma and their evolving role in the management of brain metastases...